This article discusses step-by-step best practices for automating nasal devices whose primary packaging consists of liquid-filled vials — an increasingly attractive delivery system where solutions for high-volume automation are sought-after, with prominent examples including (but not limited to) the dramatic surge in production for the opioid overdose-reversing drug naloxone.
The 700,000-square-foot plant in Holly Springs will create more than 400 jobs and support Roche and Genentech’s future portfolio of next-generation obesity medicines.
